Reviews/Osteoporosis Fracture Prevention/Bisphosphonate vertebral fracture risk
Bisphosphonate Efficacy · ostfrac_01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This claim asks whether bisphosphonate drugs lower the risk of spinal (vertebral) fractures in women who have osteoporosis after menopause. Two separate placebo-controlled trials in exactly this population found fewer new spinal fractures on treatment: one with alendronate [2] and one with ibandronate [4]. A third drug, zoledronate, also cut spinal fractures in a placebo-controlled trial [1], but the women there had osteopenia (weaker bones that have not yet reached the osteoporosis threshold) rather than osteoporosis. A very large records-based study [6] found fewer fractures in women who stuck with their bisphosphonate. Every study that spoke to this question pointed the same way — toward fewer fractures — and nothing in the corpus pointed the other way, which is why the panel landed firmly in favour of the claim.
Two independent placebo-controlled randomized trials in postmenopausal osteoporosis, each with new vertebral fractures as a prespecified endpoint, show significant reduction: alendronate cut the proportion of women with new vertebral fractures by 48 percent (3.2 percent vs 6.2 percent, P = 0.03, N=994) [2], and daily and intermittent oral ibandronate reduced vertebral fracture risk by 62% and 50% respectively (N=2946) [4]. A third bisphosphonate, zoledronate, lowered vertebral fractures (odds ratio 0.45, P=0.002) in a placebo-controlled trial, though in an osteopenic population [1]. Large claims-database data show vertebral fractures significantly lower with adherence, with relative risk reductions of 20% to 45% [6]. No included source shows the opposite direction. The contested point: The division is about breadth and exactness of fit, not direction: osteoporosis-specific placebo-controlled vertebral evidence rests on only two molecules [2], [4], and the strongest zoledronate placebo result sits in osteopenia rather than osteoporosis [1]. Active-controlled papers [5], [8] and the observational cohort [6] all point the same way but none isolates bisphosphonate-versus-nothing in the exact population.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Osteoporosis-specific placebo-controlled vertebral evidence rests on only two drugs (alendronate [2], ibandronate [4]); risedronate's placebo-controlled vertebral trial is absent from the gated corpus, so the class generalisation is partly unsupported within this corpus.
The only placebo-controlled zoledronate vertebral result [1] is in osteopenia, not osteoporosis, so it is off-population for the claim's exact wording.
Where it remains uncertain. The direct placebo-controlled osteoporosis evidence is limited to two drugs [2], [4]; the zoledronate placebo trial [1] was in osteopenia, and the supportive data [5], [6], [8] lack a placebo comparison in-population.
Aleatory
The anchoring alendronate trial turns on few events (3.2 percent vs 6.2 percent at N=994) with P = 0.03, leaving the effect estimate statistically fragile [2].
Epistemic
Placebo-controlled vertebral evidence in postmenopausal osteoporosis exists only for alendronate [2] and ibandronate [4]; no placebo-controlled risedronate vertebral trial is in the corpus.
Inferential
The observational adherence signal [6] cannot separate drug effect from the tendency of adherent patients to be healthier, so causal weight cannot rest on it.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Third bisphosphonate with a significant placebo-controlled vertebral result, though in osteopenia rather than osteoporosis.
“women who received zoledronate had a lower risk of nonvertebral fragility fractures (hazard ratio, 0.66; P=0.001), symptomatic fractures (hazard ratio, 0.73; P=0.003), vertebral fractures (odds ratio, 0.45; P=0.002), and height loss (P<0.001)”
Panel auditInternal validity: high · scope of inference: Women aged 65+ with osteopenia (not osteoporosis), treated with 18-monthly zoledronate infusions over 6 years.Key limitations: population is osteopenia not osteoporosis · older age group (65+)
Placebo-controlled RCT in postmenopausal osteoporosis: direct significant vertebral fracture reduction.
“treatment with alendronate was associated with a 48 percent reduction in the proportion of women with new vertebral fractures (3.2 percent, vs. 6.2 percent in the placebo group; P = 0.03)”
Panel auditInternal validity: high · scope of inference: Women with postmenopausal osteoporosis treated with daily oral alendronate for two to three years.Key limitations: fracture was a secondary outcome relative to BMD · modest event numbers
Second independent placebo-controlled RCT in postmenopausal osteoporosis with vertebral fracture as the primary endpoint.
“Daily and intermittent oral ibandronate significantly reduced the risk of vertebral fractures by 62% and 50%, respectively”
Panel auditInternal validity: high · scope of inference: Postmenopausal women with osteoporosis treated with daily or intermittent oral ibandronate over three years.Key limitations: no confidence intervals or p values reported in abstract · intermittent regimen details complex
The trial reports teriparatide superiority over the bisphosphonate for new vertebral fractures, which does not establish the bisphosphonate's absolute vertebral efficacy.
Panel auditInternal validity: high · scope of inference: Postmenopausal women with established severe osteoporosis; speaks to teriparatide versus risedronate, not bisphosphonate versus placebo.Key limitations: no placebo arm · head-to-head against teriparatide only · severe-osteoporosis population
4 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct placebo-controlled RCT evidence carries the claim, held just below ceiling by moderate trial sizes, one borderline P value, and the strongest zoledronate trial sitting in osteopenia rather than osteoporosis.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Placebo-controlled risedronate vertebral trial in osteoporosis. Risedronate is a widely used class member but the corpus holds only nonvertebral data for it [3], so its vertebral efficacy in-population is unsupported within this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include or conduct a placebo-controlled RCT in postmenopausal osteoporosis with new vertebral fractures as the prespecified primary endpoint.
Open question: Does risedronate reduce vertebral fracture risk versus placebo in postmenopausal osteoporosis? Why it is still open: The corpus contains only a nonvertebral pooled analysis for risedronate [3]; no placebo-controlled vertebral trial for it survives the gate.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19